title: Ileocolic free flap reconstruction, concomitant chemotherapy and radiotherapy and assessment of speech and swallowing function during management of advanced cancer of the larynx and hypopharynx: preliminary report.
abstract: CONCLUSIONS
  The new technique of ileocolic free flap reconstruction provides a better quality of life in terms of swallowing and speech for patients who have undergone laryngopharyngectomy with concomitant chemotherapy and radiotherapy (CCRT).
  
  
  OBJECTIVE
  To compare and contrast the swallowing and speech outcomes of patients who underwent total laryngopharyngectomy with ileocolic free flap reconstruction and to analyze the survival rate after surgery and CCRT.
  
  
  METHODS
  This was a follow-up study of 12 patients with advanced (stages III, IVA and IVB) laryngeal and hypopharyngeal cancer who underwent major surgery, CCRT (with one exception) and ileocolic free flap reconstruction.
  
  
  RESULTS
  All patients were able to tolerate single-stage combined management comprising total laryngopharyngectomy with or without radical neck dissection plus ileocolic free flap reconstruction and postoperative CCRT (with one exception), without immediate morbidity or mortality. Eleven patients were diagnosed with hypopharyngeal cancer and one with laryngeal cancer. The mean interval between surgery and CCRT was 34.1 days. The mean follow-up period was 16.5 months. Four patients died during the follow-up period as a result of local recurrence (n=2), distant metastasis (n=1) and suicide (n=1). One patient was alive with disease despite neck recurrence.
authors.affiliation: The Department of Otolaryngology-Head & Neck Surgery, Mackay Memorial Hospital, Taipei, Taiwan. lys@ms2.mmh.org.tw
authors.forename: Yi-Shing
authors.initials: YS
authors.lastname: Leu
authors.forename: Hung-Tao
authors.initials: HT
authors.lastname: Hsiao
authors.forename: Yuan-Ching
authors.initials: YC
authors.lastname: Chang
authors.forename: Cheng-Chien
authors.initials: CC
authors.lastname: Yang
authors.forename: Jehn-Chuan
authors.initials: JC
authors.lastname: Lee
authors.forename: Yu-Jen
authors.initials: YJ
authors.lastname: Chen
authors.forename: Yi-Fang
authors.initials: YF
authors.lastname: Chang
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy / Q000601:surgery; D002423:Cause of Death; D003106:Colon / Q000637:transplantation*; D003679:Deglutition / Q000502:physiology*; D005500:Follow-Up Studies; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000532:radiotherapy / Q000601:surgery*; D007080:Ileocecal Valve / Q000637:transplantation*; D007822:Laryngeal Neoplasms / Q000532:radiotherapy / Q000601:surgery*; D007825:Laryngectomy / Q000534:rehabilitation; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D010611:Pharyngectomy / Q000534:rehabilitation; D011788:Quality of Life; D019651:Plastic Surgery Procedures; D013060:Speech / Q000502:physiology*; D013524:Surgical Flaps; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents